Propanc Biopharma (PPCB) Other Non-Current Assets (2015 - 2025)
Propanc Biopharma (PPCB) posted quarterly Other Non-Current Assets of $2000.0 for Q4 2025, up 7.82% year-over-year from $1855.0 in Q4 2024, and down 99.98% quarter-over-quarter from $9.1 million in Q3 2025.
Propanc Biopharma (PPCB) Other Non-Current Assets (2015 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Other Non-Current Assets for 9 consecutive years, with $2000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Assets rose 7.82% year-over-year to $2000.0; the TTM figure through Dec 2025 stood at $2000.0 (up 7.82% YoY), while the FY2025 annual figure was $1971.0, down 1.84% from the prior year.
- Other Non-Current Assets fell to $2000.0 in Q4 2025 per PPCB's latest filing, from $9.1 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $12.7 million in Q1 2025 and bottomed at $1855.0 in Q4 2024.
- Historically, Other Non-Current Assets has averaged $1.1 million across 5 years, with a median of $2043.0 in 2022.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets retreated 10.81% — and 2025, when it soared 649293.76%.
- Propanc Biopharma's Other Non-Current Assets stood at $2181.0 in 2021, then declined by 6.37% to $2042.0 in 2022, then advanced by 0.1% to $2044.0 in 2023, then declined by 9.25% to $1855.0 in 2024, then grew by 7.82% to $2000.0 in 2025.
- Business Quant data shows PPCB's Other Non-Current Assets at $2000.0 in Q4 2025, $9.1 million in Q3 2025, and $1971.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 65.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 104.44 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 62.96 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 202.31 Mn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | 7.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2,000.00 |
| Sep 30, 2025 | 9.14 Mn |
| Jun 30, 2025 | 1,971.00 |
| Mar 31, 2025 | 12.70 Mn |
| Dec 31, 2024 | 1,855.00 |
| Sep 30, 2024 | 2,081.00 |
| Jun 30, 2024 | 2,008.00 |
| Mar 31, 2024 | 1,955.00 |
| Dec 31, 2023 | 2,044.00 |
| Sep 30, 2023 | 1,928.00 |
| Jun 30, 2023 | 1,999.00 |
| Mar 31, 2023 | 2,009.00 |
| Dec 31, 2022 | 2,042.00 |
| Sep 30, 2022 | 1,930.00 |
| Jun 30, 2022 | 2,075.00 |
| Mar 31, 2022 | 2,248.00 |
| Dec 31, 2021 | 2,181.00 |
| Sep 30, 2021 | 2,164.00 |
| Jun 30, 2021 | 2,250.00 |
| Mar 31, 2021 | 2,285.00 |